Comparison

Anti-Human EMAP-II - 25 µg

Item no. LEIN-E136-25ug
Manufacturer Leinco Technologies
Amount 25 ug
Quantity options 100 ug 25 ug
Category
Type Antibody Primary
Applications WB, IHC
Specific against Human (Homo sapiens)
Host Caprine
Citations 1. Ten Hagen, TL. et al. (2004) Anticancer Res. 24: 2243
2. Schwarz, RE. et al. (2009) Lab Invest. 89: 38
NCBI 9255
ECLASS 10.1 32160702
ECLASS 11.0 32160702
UNSPSC 12352203
Shipping Condition Room temperature
Available
Manufacturer - Applications
IHC FFPE, WB
Manufacturer - Category
Polyclonal Antibodies>Growth Factors & Cytokines
Manufacturer - Targets
EMAP-II
Country of Origin
USA
Shipping Temperature
Next Day Ambient
Storage Conditions
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Product Description
Endothelial monocyte activating polypeptide II (EMAP II) is a pro-inflammatory cytokine with anti-angiogenic properties. This protein was discovered in the supernatant of Meth-A fibrosarcoma cells and was shown to enhance the induction of the procoagulant Tissue Factor (TF) on endothelial cells. Besides up-regulation of TF mRNA, EMAP II increases cellular receptors for TNF on endothelial cells, which is likely to enhance the predisposition of tumors to undergo thrombosis and hemorrhagic necrosis, once challenged with TNF.1 EMAP II functions as a potent inhibitor of primary and metastatic tumor growth, has strong inhibitory effects on endothelial cells and can reduce intratumoral expression of the angiogenesis inducer vascular endothelial growth factor (VEGF). 2 It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils.
Background
Endothelial monocyte activating polypeptide II (EMAP II) is a pro-inflammatory cytokine with anti-angiogenic properties. This protein was discovered in the supernatant of Meth-A fibrosarcoma cells and was shown to enhance the induction of the procoagulant Tissue Factor (TF) on endothelial cells. Besides up-regulation of TF mRNA, EMAP II increases cellular receptors for TNF on endothelial cells, which is likely to enhance the predisposition of tumors to undergo thrombosis and hemorrhagic necrosis, once challenged with TNF.1 EMAP II functions as a potent inhibitor of primary and metastatic tumor growth, has strong inhibitory effects on endothelial cells and can reduce intratumoral expression of the angiogenesis inducer vascular endothelial growth factor (VEGF). 2 It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils.
Other Applications Reported In Literature
IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 5-15 µg/ml. The recommended secondary antibody for IHC is PN:G505. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.
PubMed
EMAP-II
Manufacturer - Specificity
Goat Anti-Human Endothelial Monocyte Activating Polypeptide-II (EMAP-II) recognizes Human EMAP-II. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
RRID
AB_2829986
Formulation
This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Immunogen
E. coli-Derived Recombinant Human EMAP-II
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
Polyclonal Antibody, Endothelial Monocyte Activating Polypeptide-II , EMAP-II, Human EMAP-II, Anti-Human EMAP-II, AIMP1, aminoacyl tRNA synthetase complex-interacting multifunctional protein 1, EMAP-2, EMAPII, EMAP-II, EMAPIImember 1 endothelialmonocyte-activating, endothelial-monocyte activating polypeptide II, Multisynthase complex auxiliary component p43, multisynthetase complex auxiliary component p43, SCYE1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close